Hospital Universitario Araba — Clinical Trial Site

51 Registered trials

18 Currently recruiting

Organisation

Hospital Universitario Araba

Location

Vitoria, Spain

Identifier

ORG-100039644

Address

Jose Atxotegui S/n, 09010, Spain

Departments

#2311:servicio de neurología
#3414 - Reumatología
#40863: Reumatología
3414: Reumatología
7106: Hematología
Digestivo
Functional sleep unit
Funtional sleep unit
Hematología
Hematology
infectious diseases
Internal Medicine
Medicina Interna - Sección de Enfermedades Infecciosas
Oncología
Oncology
Oncology Service
Pediatria
Pediatric
Pediatric Endocrinology
Pediatrics Endocrinology
Psychiatry
reumatologia
Rheumatology
Servicio de endocrinologia y pediatria
Servicio de Reumatología
Servicio de Reumatología -Sede Txagorritxu
Servicio de Traumatología y Cirugía Ortopédica
Sleep Unit
Unidad de Ensayos clínicos
Unidad del Sueño
Urología
Urology

Clinical trials at this site (51)

Search interface

Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS-… Recruiting

2023-505929-14-00 Systemic Lupus Erythematosus 5 2024-05-21
Frexalimab in preservation of endogenous insulin secretion compared to placebo in adults, adolescents and children on top of Insulin therapy… Recruiting

2022-500531-36-00 Type 1 diabetes mellitus 4 2024-02-02
LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting

2022-502706-33-00 Patients with invasive breast cancer in early stages 6 2018-01-10
A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended

2024-516609-22-00 Primary Sjögren’s Disease 5 2025-04-15
Phase 3 Study of ALXN1850 versus Placebo in Adolescent and Adult Participants with HPP who have not previously been treated with Asfotase Al… Ended

2023-505673-32-00 Hypophosphatasia 5 2024-08-05
A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended

2023-503923-24-00 Sjögren’s Syndrome With Moderate-toSevere Symptom State 5 2024-07-22
A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Par… Ended

2022-501396-62-00 Relapsed Refractory Multiple Myeloma 5 2023-12-12
“Randomized, double-blind clinical trial to assess the efficacy of tranexamic acid in reducing blood loss in patients with hip fracture”. Ended

2024-519349-31-00 Hip fracture 6 2023-05-17
A Trial to Evaluate the Long-term Safety and Tolerability of TAK-861 Ended

2023-508462-15-00 Narcolepsy with Cataplexy (Narcolepsy Type 1) 10 2023-04-27
Phase 3 study to evaluate two regimens of ianalumab on top of standardof- care therapy in patients with systemic lupus erythematosus (SIRIUS… Ended

2023-508498-97-00 Systemic Lupus Erythematosus 5 2023-02-03
Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT Ended

2024-517008-12-00 Newly-diagnosed multiple myeloma (NDMM) 5 2022-10-14
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509372-41-00 Multiple Sclerosis 5 2022-01-30
A study to learn if dapirolizumab pegol is safe and works long-term in people with systemic lupus erythematosus Ended

2023-506368-14-00 Systemic lupus erythematosus (SLE) 5 2021-09-07
A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr… Ended

2023-504684-16-00 follicular lymphoma (FL) and marginal zone lymphoma (MZ 5 2021-06-05
Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients… Ended

2022-500237-92-00 Newly-diagnosed high-intermediate and high-risk diffuse 5 2021-04-23
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended

2023-510357-42-00 hormone receptor (HR)-positive, HER2-negative, early br 5 2019-05-22
Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 year… Ended

2024-516905-22-00 Multiple myeloma 5 2018-10-22
A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy Ended

2024-511998-30-00 Narcolepsy with Cataplexy (Narcolepsy Type 1) 5 2024-10-18
A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy Ended

2023-508465-32-00 Narcolepsy with Cataplexy (Narcolepsy Type 1) 5 2024-09-03
A study to learn about how elinzanetant works and how safe it is in women having sleep disturbances associated with menopause Ended

2023-504955-28-01 Sleep disturbances associated with menopause 4 2024-03-14
PH2a, VH3739937 Proof-Of-Concept in TN HIV-1 Infected Adults Ended

2023-505780-37-00 HIV Infections 4 2023-12-21
Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2… Ended

2024-512590-27-00 Non-resectable locally advanced or metastatic HER2-posi 9 2023-03-08
A Study of Baricitinib (LY3009104) in Children With COVID-19 (COV-BARRIER) Ended

2024-516824-32-00 Covid19 Corona Virus Infection 5 2021-11-15